TRIM21 and diffuse large B-cell lymphoma: Thus, the absence of TRIM21/Ro52 results in aberrant NF-κB activation, which is also explicitly required for the proliferation of activated B-cell DLBCL, the main subtype of DLBCL found in SLE patients [30–32].